Venus Remedies (BOM:526953) Cyclically Adjusted Revenue per Share: ₹517.64 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526953 Venus Remedies Ltd BOM:526953
53 GF Score
Price ₹1,578.80
GF Value ₹523.40
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Venus Remedies Cyclically Adjusted Revenue per Share?

Venus Remedies BOM:526953 +2.11% 53 Cyclically Adjusted Revenue per Share is ₹517.64 as of Jun. 2026. GuruFocus rates BOM:526953 with a GF Score™ of 53/100 and a GF Value™ of ₹523.40 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Venus Remedies's adjusted revenue per share for the three months ended in Jun. 2026 was ₹133.777. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹517.64 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Venus Remedies's average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-01), Venus Remedies's current stock price is ₹1578.80. Venus Remedies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹517.64. Venus Remedies's Cyclically Adjusted PS Ratio of today is 3.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Venus Remedies was 3.72. The lowest was 0.57. And the median was 0.86.


Venus Remedies  (BOM:526953) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Venus Remedies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1578.80/517.64
=3.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Venus Remedies was 3.72. The lowest was 0.57. And the median was 0.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Venus Remedies Cyclically Adjusted Revenue per Share Related Terms


Venus Remedies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Venus Remedies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies Cyclically Adjusted Revenue per Share Chart

Venus Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 506.95 522.56

Venus Remedies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 510.90 520.70 524.33 522.56 517.64

BOM:526953 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Remedies Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Venus Remedies's Cyclically Adjusted PS Ratio falls into.


BOM:526953
53GF Score
Venus Remedies Ltd BOM:526953
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Remedies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Venus Remedies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=133.777/166.1454*166.1454
=133.777

Current CPI (Jun. 2026) = 166.1454.

Venus Remedies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 114.580 83.774 227.241
201303 126.991 85.687 246.233
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 54.292 111.317 81.034
201809 72.592 115.142 104.748
201812 61.562 115.142 88.832
201903 69.838 118.202 98.165
201906 59.671 120.880 82.016
201909 71.838 123.175 96.899
201912 78.536 126.235 103.366
202003 65.710 124.705 87.546
202006 153.065 127.000 200.244
202009 102.105 130.118 130.376
202012 98.767 130.889 125.371
202103 90.209 131.771 113.742
202106 98.304 134.084 121.810
202109 151.549 135.847 185.349
202112 92.867 138.161 111.677
202203 107.595 138.822 128.772
202206 107.152 142.347 125.066
202209 104.724 144.661 120.277
202212 87.408 145.763 99.631
202303 114.937 146.865 130.026
202306 70.967 150.280 78.459
202309 125.539 151.492 137.682
202312 107.407 152.924 116.693
202403 138.634 153.035 150.511
202406 81.902 155.789 87.347
202409 127.454 157.882 134.125
202412 132.027 158.323 138.550
202503 147.872 157.552 155.938
202506 102.603 159.755 106.707
202509 144.198 162.289 147.624
202512 134.875 163.281 137.241
202603 194.075 164.272 196.288
202606 133.777 166.145 133.777

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹517.64 mean?
Venus Remedies (BOM:526953) has a Cyclically Adjusted Revenue per Share of ₹517.64 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Venus Remedies and its competitors.
Is Venus Remedies' Cyclically Adjusted Revenue per Share too high?
Venus Remedies' current Cyclically Adjusted Revenue per Share is ₹517.64. Overall, Venus Remedies has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Cyclically Adjusted Revenue per Share compare to ZTS?
Venus Remedies' Cyclically Adjusted Revenue per Share of ₹517.64 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Venus Remedies and its competitors. Venus Remedies's current Cyclically Adjusted Revenue per Share is ₹517.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹523.40, compared to a current price of ₹1,578.80 — trading 201.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹517.64. Venus Remedies' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Cyclically Adjusted Revenue per Share is ₹517.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (BOM:526953) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,578.80 is trading 201.6% above its estimated GF Value™ of ₹523.40. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for BOM:526953:

  • Cyclically Adjusted Revenue per Share: ₹517.64
  • GF Value™: ₹523.40 vs. price of ₹1,578.80 (201.6% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Venus Remedies Business Description

Other Exchanges VENUSREM:India
Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
53GF Score

Get the complete analysis for BOM:526953

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,578.80
Price
₹523.40
GF Value